Premium
Heparin or bivalirudin for non‐primary PCI : Beware of neat and simple answers…
Author(s) -
Deliargyris Efthymios N.,
Kimmelstiel Carey
Publication year - 2017
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27308
Subject(s) - bivalirudin , medicine , conventional pci , heparin , anticoagulant , intensive care medicine , cardiology , myocardial infarction
Key Points The debate regarding the choice of heparin or bivalirudin as the preferred anticoagulant in PCI is still ongoing Nonrandomized registry data are severely limited for comparative analyses and should therefore always be interpreted with caution Clinicians should resist simplistic data interpretations or populist cries relating to cost, but rather focus on valid benefit:risk analyses for their clinical decision making